OFFICIAL ABSTRACT and CERTIFICATION

Targeted inhibition of a novel MALT1 and MAPK signaling network synergistically suppresses aggressive B cell lymphoma growth

Hammad Hassan

Ossining High School, Ossining, NY, USA

Mucosa associated lymphoid translocation protein 1 (MALT1) mediates pathogenesis of the Activated B cell subtype of Diffuse large B cell lymphoma (ABC DLBCL) via cleaving negative regulators of the Nuclear Factor kappa Beta pathway (Nf-kB) pathway. Targeted degradation of MALT1 proteolytic domain induces cytotoxicity among ABC DLBCLs but unknown resistance mechanisms have prevented clinical translation of MALT1 protease inhibitors. This study sought to identify novel targets on MALT1 by suppressing its caspase domain and analyzing MALT1 protein expression at varying time points. Treatment of ABC DLBCL cell lines HBL-1, OCI-ly3, and TMD8 with MALT1 protease inhibitors SCM-02-138, MI-2, and Mepazine did not affect the MALT1 expression at 1hr time point, but MALT1 expression upregulated after the 48 and 96 hr. timepoints. Western Blot analysis further suggested that MALT1 protease suppression induces upregulation of the MAPK signaling pathway by activating the ERK kinase, uncovering a novel Nf-kB and MAPK signaling crosstalk network. ABC DLBCLs were then administered with Trametinib in order to suppress ERK, which also led to attenuation of the MALT protein expression. To address phenotypical implications of this network, fixed ratio growth inhibition experiments were conducted, which elucidated that combinatorial inhibition of MALT1 and ERK suppresses ABC DLBCL progression. Chou-Talalay analysis further suggested that combinatorial inhibition induces synergistictic cytotoxicity (CI < 1) among lymphoma clones. Taken together, by diagnosing a novel signaling network and developing a therapeutic approach, this study has provided a rationale for exploring combination therapies for numerous MALT1-addicted tumors.

- 1. As a part of this research project, the student directly handled, manipulated, or interacted with (check ALL that apply):
 - ☐ human participants
- potentially hazardous biological agents
- □ vertebrate animals
- ☐ microorganisms
- □ rDNA
- ☐ tissue
- 2. I/we worked or used equipment in a regulated research institution □ No Yes or industrial setting:
- 3. This project is a continuation of previous research.
- ☐ Yes ■ No
- 4. My display board includes non-published photographs/visual ☐ Yes ■ No depictions of humans (other than myself):
- 5. This abstract describes only procedures performed by me/us, □ No reflects my/our own independent research, and represents one year's work only
- □ No Yes 6. I/we hereby certify that the abstract and responses to the above statements are correct and properly reflect my/our own work.

This stamp or embossed seal attests that this project is in compliance with all federal and state laws and regulations and that all appropriate reviews and approvals have been obtained including the final clearance by the Scientific Review Committee.

Category Pick one only mark an "X" in box at right

Animal Sciences

Behavioral & Social Sciences

Biochemistry

Biomedical & Health Sciences

Biomedical Engineering

Cellular & Molecular Biology

Chemistry

Computational Biology & Bioinformatics

Earth & Environmental Sciences

Embedded Systems

Energy: Sustainable Materials and Design

Engineering Mechanics

Environmental Engineering

Materials Science

Mathematics

Microbiology

Physics & Astronomy

Plant Sciences

Robotics & Intelligent Machines

Systems Software

Translational Medical Sciences

